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Abstract
Background: Clustered randomised controlled trials (CRCTs) are increasingly common in primary care. Outcomes
within the same cluster tend to be correlated with one another. In sample size calculations, estimates of the
intra-cluster correlation coefficient (ICC) are needed to allow for this nonindependence. In studies with observations
over more than one time period, estimates of the inter-period correlation (IPC) and the within-period correlation
(WPC) are also needed.
Methods: This is a retrospective cross-sectional study of all patients aged 18 or over with a diagnosis of type-2
diabetes, from The Health Improvement Network (THIN) database, between 1 October 2007 and 31 March 2010. We
report estimates of the ICC, IPC, and WPC for typical outcomes using unadjusted and adjusted generalised linear
mixed models with cluster and cluster by period random effects. For binary outcomes we report on the
proportions scale, which is the appropriate scale for trial design. Estimated ICCs were compared to those reported
from a systematic search of CRCTs undertaken in primary care in the UK in type-2 diabetes.
Results: Data from 430 general practices, with a median [IQR] number of diabetics per practice of 241 [150–351],
were analysed. The ICC for HbA1c was 0.032 (95 % CI 0.026–0.038). For a two-period (each of 12 months) design,
the WPC for HbA1c was 0.035 (95 % CI 0.030–0.040) and the IPC was 0.019 (95 % CI 0.014–0.026). The difference
between the WPC and the IPC indicates a decay of correlation over time. Following dichotomisation at 7.5 %, the
ICC for HbA1c was 0.026 (95 % CI 0.022–0.030). ICCs for other clinical measurements and clinical outcomes are
presented. A systematic search of ICCs used in the design of CRCTs involving type-2 diabetes with HbA1c
(undichotomised) as the outcome found that published trials tended to use more conservative ICC values (median
0.047, IQR 0.047–0.050) than those reported here.
Conclusions: These estimates of ICCs, IPCs, and WPCs for a variety of outcomes commonly used in diabetes trials
can be useful for the design of CRCTs. In studies with observations taken at different time-points, the correlation of
observations may decay over time, as reflected in lower values for the IPC than for the ICC. The IPC and WPC
estimates are the first reported for UK primary care data.
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Background
Diabetes is an important public health issue [1] and an
increasing number of clinical trials are being conducted
to improve care for patients with diabetes. Increasingly,
interventions aimed at improving the quality of care are
evaluated using cluster randomised controlled trials
(CRCTs) [2–5]. Whilst observations used in the evalu-
ation may still be made at the individual level, random-
isation at the cluster level (such as GP surgery) will
often be necessary [5–7] and is increasingly being used
[8]. In CRCTs patients within the same cluster tend to
more similar than patients from differing clusters [7, 9].
Thus, the observations within a cluster may not be inde-
pendent, and the design and analysis of CRCTs should
acknowledge this [5, 10–13].
Important outcomes in trials of diabetes include clin-
ical measurements, such as glycosylated haemoglobin
(HbA1c) (both as a continuous and dichotomised out-
come) [14], body mass index (BMI) [15], cholesterol
[16], blood pressure [17], or the incidence of macrovas-
cular and microvascular outcomes [18, 19].
Sample size calculations for an individually rando-
mised controlled trial (RCT) are relatively straightfor-
ward, but for a CRCT it is necessary to account for the
nonindependence [10–12]. A design effect can be used
to inflate the sample size of an RCT to that required in a
CRCT [9, 20]. For a trial with equal cluster sizes, the de-
sign effect is calculated as:
1þ m−1ð Þρ: ð1Þ
Here m is the cluster size and ρ is the correlation
between patients within a cluster [21]. This correlation
has important implications for the sample size required
[22, 23].
The majority of CRCTs have a parallel design. That is
to say, clusters are allocated to either intervention or
control. However, increasingly, the value of alternative
cluster designs is being appreciated. Some alternative de-
signs include the cluster cross-over [24], the stepped
wedge [25, 26], and the dog-leg [27, 28]. In these alter-
native designs repeated cross-sectional samples are taken
from each cluster over multiple time periods. It is be-
coming increasingly recognised that observations from
the same cluster and same period are likely to be more
highly correlated than observations in the same cluster
but at different periods [29–32]. This leads to the notion
of a within-period cluster correlation (WPC) and an
inter-period cluster correlation (IPC). Unfortunately,
there is little or no empirical literature to inform likely
values for these parameters at the design stage [28, 29].
For a trial to be powered correctly, an accurate esti-
mate of the correlation of observations within a cluster
is required. In the past, many type-2 diabetes trials in
primary care have failed to report this correlation, for-
cing many planned trials to use ad hoc values at the de-
sign stage [33]. This leads to inaccurate sample size
estimates and (sometimes) to underpowered trials. Typ-
ically, this correlation is assumed to be time independent
– and a single intra-cluster correlation coefficient (ICC)
is used in the sample size calculation. This assumption
may not always be valid. For designs with observations
taken over multiple time periods, estimates of the WPC
and IPC are vital in the sample size calculation [28, 29].
These can be obtained from routinely collected data, in
a similar way to ordinary ICCs [34, 35].
Our objective here is to estimate ICCs for typical trial
outcomes related to type-2 diabetes using anonymised
patient data from The Health Improvement Network
database [36]. We additionally report estimates of the
WPC and the IPC for a subset of continuous outcomes.
Finally, we review previous CRCTs in type-2 diabetes to
compare the ICCs estimated in this paper to those previ-
ously used.
Methods
Correlation of observations in a cluster trial
The quantity ρ in Eq. 1 is defined as the correlation be-
tween two randomly selected observations within the
same cluster. Typically, an assumption is made that this
correlation is independent of the timing of the observa-
tions. This property is consistent with a decomposition
of the total variance into two independent components
representing variation between clusters and between
subjects (within clusters). In view of this, the ICC can be
defined as the proportion of the variance that is attribut-
able to the between-cluster variance, given as:
σb2
σb2 þ σw2 ; ð2Þ
where σb
2 and σw
2 represent the between- and within-
cluster variance components.
Cluster trials are typically analysed using a multilevel
linear model. If the correlation between observations in
a cluster is independent of when they are taken, an ap-
proach using the ratio of variances is a simple method
to estimate the ICC. This approach is taken throughout
the paper whenever an estimated ICC is reported.
Time-dependent correlation
In some contexts, a model based on the assumption of
time-independent correlations is flawed. An alternative
model can be fitted to the data by splitting time into a
number of (equal) periods. In this formulation, constant
correlations are assumed: (1) for any two observations in
the cluster from the same time period (WPC); and (2)
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for any two observations from the same cluster in differ-
ent time periods (IPC).
These assumptions are consistent with a variance-
decomposition into three independent components:
between clusters (σe
2); between time periods (within
clusters) (σc
2); and between subjects (within time period
and cluster) (σt
2).
Now, the WPC is the correlation of observations be-
tween two patients in the same cluster from the same
time period. This can be calculated as:
σc2 þ σ t2
σc2 þ σe2 þ σ t2 :
The IPC is the correlation of observations between
two patients in the cluster from different time periods,
and is calculated as:
σc2
σc2 þ σe2 þ σ t2 :
In this framework, the correlation, ρ, between two ran-
domly selected observations within the same cluster is
given by a within-cluster correlation (WCC) defined by:
WCC ¼ IPC þ 1
ntp
WPC−IPCð Þ: ð3Þ
Here ntp is the number of time periods in the study. It
is assumed that each time period contains an equal
number of observations.
The ratio of the IPC to the WPC is known as the clus-
ter autocorrelation (CA), which is the correlation be-
tween the cluster level mean outcome over time [28].
The cluster autocorrelation has been established as key
to sample size formula for studies with a repeated cross-
sectional design [37]. We present estimates of the CA
alongside the IPC and WPC.
In the absence of period effects, the CA = 1, indicating
that the time-dependent model is unnecessary. In this
setting, WCC =WPC = IPC. Otherwise it follows from
the definitions that WPC >WCC > IPC.
Correlation of binary outcomes
In the context of a clinical trial, data are often dichotom-
ous – recording the presence or absence of a particular
clinical outcome. The ICC that appears in the design ef-
fect is then defined as the correlation between two bin-
ary outcomes from two patients in the same cluster. In
such cases, sample size calculations will typically entail a
normal approximation to the binomial distribution
which describes the number of positive outcomes in a
sample of fixed size. Nevertheless the analysis of dichot-
omous outcomes in cluster trials is often conducted via
a multilevel logistic model. In such models the observed
binary outcome may be conceptualised as having arisen
by dichotomising a continuous latent scale. When these
models are fitted in some analysis packages (e.g. Stata) a
type of ICC is presented which relates not to the ob-
served binary outcomes but to this unobservable latent
scale. It takes the form:
σb2
σb2 þ π2=3 ;
where σb
2 is the between-cluster component of variance
on the latent scale and the term π2/3 is associated with
the logistic distribution used to generate the binary
model.
Since this version of the ICC refers to the unobserv-
able latent scale, rather than the correlation between the
binary outcomes of two patients from within the same
cluster, this ICC should not be used directly to compute
design effects for sample size calculations. In principle, a
latent ICC from a logistic regression model can be con-
verted to a natural ICC on the proportion scale for the
raw binary data, taking account of the prevalence of the
outcome – see, for example, the table presented by
Eldridge et al. [21]. Throughout this paper we maintain
the distinction between a natural ICC on the proportion
scale and a latent ICC for binary data. It is the natural
ICC on the proportion scale that contributes to the cal-
culation of design effects.
Outcome variables
The aim was to investigate the correlation of all rou-
tinely recorded variables that might be clinically relevant
to a trial undertaken in type-2 diabetes. The outcome
variables were divided into three categories: clinical mea-
sures, medication, and clinical outcomes. Clinical mea-
sures included HbA1c, systolic blood pressure, diastolic
blood pressure, BMI, total cholesterol level, and high-
density lipoprotein (HDL) cholesterol level. Medication
measurements involved insulin and other hypoglycaemic
medications. The clinical outcomes were a first diagnosis
of: atrial fibrillation, chronic kidney disease, chronic ob-
structive pulmonary disease (COPD), ischaemic heart
disease (IHD), peripheral vascular disease, and stroke.
Patients who had suffered an event prior to the study
were excluded from the analysis for that outcome.
Dichotomisation of continuous outcomes
In practice, many trials use dichotomised values of con-
tinuous outcome measures [38, 39], and so we generated
dichotomised values for each continuous outcome. A
threshold value of 7.5 % was chosen for HbA1c as NICE
guidelines state that 7.5 % indicates inadequate control
[40], in addition to being used in previous studies [41].
Multiple recommendations have been made that total
cholesterol levels should be below 4.0 mmol/L and HDL
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cholesterol levels be above 1.2 mmol/L [42, 43]. Two
relevant cut-points were used for both systolic blood
pressure and BMI. For systolic blood pressure, a value of
140 mmHg is the upper limit recommended for patients
with type-2 diabetes [40]. A lower value of 130 mmHg is
the target that health care professionals aim to reduce
systolic blood pressure to in patients who suffer from
kidney and eye problems, or those who have suffered a
stroke [40]. Two cut-points were chosen for BMI to cor-
respond to the categories of overweight (25 kg/m2) and
moderately obese (30 kg/m2).
Measurement periods
A cross-sectional sample of measurements taken over a
15-month period was used (1 January 2009 to 31 March
2010), to reflect the NICE quality and outcomes frame-
work (QOF) [44], which monitors measurements taken
for patients over a 15-month period. To estimate the
IPC and WPC an additional 15 months (1 October 2007
to 31 December 2008) of data is used to estimate the
time-dependent correlation, creating two 15-month time
periods.
Since the measuring unit of HbA1c changed in 2009
from % to mmol/mol, the consistency in reporting is
likely to be poor around this time. In view of this, we
consider a slight variation, and a cross-sectional sample
of measurements taken over a 12-month period was
used (1 January 2008 to 31 December 2008). An add-
itional 12 months (1 January 2007 to 31 December
2007) of data contributes towards the estimation of the
IPC and WPC.
The Health Improvement Network
The retrospective cross-section of patients with type-2
diabetes was formed using data from The Health Im-
provement Network (THIN) database [36]. Participating
general practices contributed anonymised demographics,
prescribing information, and clinical data for more than
3.7 million patients throughout the UK. All practices
used the Vision computer system.
All patients over 18 years of age were included if a diag-
nosis of type-2 diabetes, indicated by the appropriate ‘Read
codes’, was made before the study index date. Read codes
are a coded thesaurus of clinical terms that are used in the
recording of patient data in primary care electronic medical
records in the UK. The general practices were required to
have been using the Vision computer system for a mini-
mum of a 1 year period prior to the study index date, and
to have an acceptable mortality reporting (AMR) date (an
indicator of practice quality) [45].
Data summary
The included population was summarised by describing
both patient and practice characteristics using appropriate
summary statistics. General practice characteristics in-
clude the total number of practices, location (country) of
the practice, and practice inclusion size (the number of
patients from each practice satisfying the entry criteria).
Patient characteristics (of the included population) were
age (years), gender, location (country of residence), and
deprivation quintiles.
We also summarised potential trial outcomes using
suitable summary statistics. Outcomes included clinical
measures, onset of clinical outcomes, and the prescrip-
tion of medication. Although the HbA1c variable ex-
hibits skewness, both mean and median values were
given as it is assumed to be normally distributed in
many trials.
Variation across practices in mean (or median) clinical
measures, clinical outcomes, and the prescription of
medication, was summarised by reporting the interquar-
tile range (IQR) of the practice mean (or median) values.
Statistical models
Generalised linear mixed models were used to estimate
the ICCs with cluster (general practice) modelled as the
random effect. Both adjusted and unadjusted ICCs were
estimated, with adjustments made for age, sex, location,
and deprivation quintiles. All clinical measures were pre-
sented in both continuous and dichotomised form.
For continuous outcomes, a mixed-effects linear
model was fitted and the ICC was estimated as the ratio
of the between-cluster variance (of the outcome) to the
total variance of the outcome.
For binary outcomes, a mixed-effects linear model was
fitted to estimate the natural ICC on the proportion
scale, whilst a mixed-effects logistic regression was fitted
to estimate the latent ICC.
To estimate the WPC, IPC, and CA, a generalised lin-
ear mixed model was used, with two random effects –
one for cluster (general practice) and one for a cluster
by period interaction.
All analysis was performed using Stata 13 (StataCorp,
College Station, TX, USA). Linear models were fitted
using the mixed command, and logistic models fitted
using the melogit command. Estimates of the ICC,
WPC, and IPC were produced using the estat function.
Search of previous CRCTs
A systematic search of previous CRCTs investigating
diabetes in primary care in the UK was carried out in
order to compare the results from this analysis to values
used in previous CRCTs.
The following sources were used: Medline (1950 to
week 2 of May 2013), Medline InProcess (May 2013),
and Google Scholar (May 2013). The searches were
conducted in May 2013. The following phrases were
used: type-II diabetes, type-2 diabetes, diabetes mellitus,
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diabetes mellitus non-insulin-dependent, adult-onset
diabetes mellitus, cluster trial, clustered trial, cluster
analysis, cluster analyses, clustering, disease clustering,
cluster RCT, and cluster randomised (randomized) con-
trolled trial. The search was limited to the English
language.
Studies from all fields of research were included if they
described a CRCT that had taken place, or was planned
to take place, that used UK general practices as the unit
of randomisation. Studies were included if at least one of
the trial outcomes were: HbA1c levels, systolic blood
pressure, diastolic blood pressure, BMI, total cholesterol,
HDL cholesterol, the prescription of insulin, or the onset
of microvascular and macrovascular outcomes.
Since the focus is on the ICCs used in the design of a
CRCT, all trials in which individuals were the unit of
randomisation were excluded from the study. All trials
that did not take place in the UK were also excluded
since ICC estimates may be affected by the country in
which the trial is taking place. All trials with unspecified
outcomes were excluded. Trials that aim to prevent the
onset of diabetes were also excluded. Any duplicate or
follow-on publications from the same trial were included
as a single study.
Titles and abstracts retrieved from the search process
were screened to obtain relevant trials. Full articles were
then read and classified as either included or excluded.
All included articles were then used for data extraction.
The extracted information consisted of: study authors,
outcome used, value of ICC used in the sample size cal-
culation, standard deviation used in the sample size cal-
culation (where appropriate), and the ICC estimated
from the trial data (if reported).
Results
Analysis of THIN data
A summary of patient and practice characteristics is
given in Table 1. A total of 112,633 patients from 430
practices covering all areas of the UK, were included in
the study. The socioeconomic status was fairly balanced
across the categories. The median value of HbA1c (%)
(7.05) was lower than the mean value (7.35), highlighting
the positive skewness that is exhibited by the variable.
Atrial fibrillation was the most common clinical out-
come (1.06 %), whilst chronic kidney disease was the
least common (0.35 %).
Table 2 summarises the proportion of patients whose
clinical measures exceed the dichotomised value of the
outcomes. Of the participants with a recording for HbA1c,
over one third (34.2 %) had an HbA1c % exceeding 7.5 %.
It was also found that over one half (57.2 %) exceeded the
target systolic blood pressure of 130 mmHg whilst approxi-
mately one quarter (25.2 %) exceeded 140 mmHg. A large
proportion (83.1 %) of the population were categorised as
being overweight (>25 kg/m2) (34.8 %), obese (>30 kg/m2)
(27.3 %), or morbidly obese (>35 kg/m2) (21.0 %).
The variation of both the clinical outcomes and
clinical measures across practices is given in Table 3.
The interquartile range represents the practice mean
outcome for the central 50 % of practices. ICC esti-
mates and corresponding standard errors (SE) for
clinical measures of continuous nature are given in
Table 4 and compared further in Fig. 1. For clinical
measurements, in continuous form, the ICCs had a
median of 0.026 [IQR 0.020–0.032] and were similar
when adjusting for confounding factors (median
0.025, IQR 0.020–0.029). The ICC for HbA1c was es-
timated to be 0.032 (SE 0.003) when using an un-
adjusted model and 0.032 (SE 0.003) after adjustment
for patient-level factors.
After dichotomising, the ICCs of clinical measures had
a median latent ICC of 0.037 [IQR 0.023–0.055] and a
median natural ICC on the proportion scale of 0.028
[IQR 0.018–0.039]. Clinical outcomes had a median la-
tent ICC of 0.094 [IQR 0.027–0.136] and a median nat-
ural ICC on the proportion scale of 0.003 [IQR 0.001–
0.005]. When comparing two clinical outcomes with
similar prevalence, it is expected that the outcome
with a larger IQR of the practice average would have
a larger ICC. This is consistent with the larger nat-
ural and latent ICCs (Table 5) that are associated
with COPD compared to IHD, both of which have a
prevalence of around 1 % (Table 1). Figure 1 further
highlights that latent ICCs were larger than natural
ICCs on the proportion scale for binary outcomes,
but also that the range of latent ICCs is higher than
natural ICCs.
Estimates of the WPC, IPC, and CA for the two-
period study design are given in Table 6. For HbA1c, the
correlation between two patients during the same (12-
month) time period (WPC) was estimated at 0.035 (SE
0.003). The correlation between two patients at different
(12-month) time periods (IPC) is 0.019 (SE 0.003). There
is evidence to suggest that the variance component re-
lated to time period is non-zero, and so the correlation
of observations seems to decay over time. Excluding
HbA1c, in the two-period (each of 15 months) design,
the decay of correlation is further highlighted by the me-
dian WPC (0.021, IQR 0.021–0.032) and median IPC
(0.018, IQR 0.013–0.021).
The median cluster autocorrelation (excluding HbA1c)
is 0.649 [IQR 0.612–0.692], with total cholesterol having
the smallest value – indicating that correlation of total
cholesterol observations for patients in different time pe-
riods is much smaller than the correlation of observa-
tions in the same time period. Adjusting for covariates
had some impact on correlation estimates. For total
cholesterol, the CA in the adjusted model (0.281) was
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much lower than the unadjusted model (0.486). Con-
versely, HbA1c had much higher CA in the adjusted
model (0.747) than in the unadjusted model (0.612).
Systematic search
Our search strategy found 133 relevant articles. From
this, 70 articles were of irrelevant outcome or trial type
(individually randomised design, genetics of diabetes,
cross-sectional studies, etc.), 36 were excluded due to
the population of the trials (not of UK origin), 7 articles
were screening programmes, 6 aimed to prevent dia-
betes, and 2 articles were excluded as they measure
prevalence of diabetes. Of the 12 trials remaining, 3 du-
plicates were removed, leaving 9 articles that met the in-
clusion criteria (see Additional file 1).
One CRCT used the cluster as unit of randomisation
but did not use an ICC when calculating sample size [46].
Of the remaining eight CRCTs, two CRCTs [39, 47] used
multiple outcomes and calculated sample sizes for each
outcome of relevance. Seven CRCTs [14, 39, 47–51] used
HbA1c as an outcome measure, three [38, 39, 47] used
systolic blood pressure, and two [39, 47] used cholesterol.
However, cholesterol was not used as a sole outcome
measure, only as secondary measure alongside both
HbA1c and blood pressure. Of these eight CRCTs, two
[38, 39] used a binary outcome, and seven [14, 39, 47–51]
used a continuous outcome (one used both a binary and
continuous outcome [39]).
The median [IQR] ICC used to power the study for
trials in which HbA1c % was the primary outcome was
0.047 [0.047–0.05] (Table 7). The two CRCTs [39, 47] in
which total cholesterol (mmol/L) was the main outcome
used 0.047 and 0.06 (binary outcome) as the ICC whilst
the three CRCTs using blood pressure (mmHg) as the
main outcome [38, 39, 47] used ICCs of 0.001 (binary
outcome), 0.02 (binary outcome), and 0.035. The stand-
ard deviation of HbA1c % used was reported in six trials
[14, 39, 47, 49–51], of which the mean value was 1.7.
The results of this paper found a similar standard devi-
ation of 1.4 for HbA1c %, whereas the ICC found by this
paper was lower (0.032 versus 0.047).
Table 1 Summary of study population (THIN database) by
practice and patient-level characteristics
Practice characteristics
Number of general practices 430
General practice sizea, median [IQR] 241 [150–351]
Location, N (%)
England 322 (75)




Number of patients 112,633
Age, median [IQR] 70 [60–78]
Sex (male), N (%) 61,944 (55)
Location, N (%)
England 88,838 (79)
Northern Ireland 3464 (3)
Scotland 12,461 (11)
Wales 7870 (7)
Deprivation quintiles, N (%)




5 (most deprived) 16,352 (15)
Unknown 4237 (4)
Clinical measures
HbA1c (%), median [IQR] 7.05 [6.4–7.9]
HbA1c (%), mean (SD) 7.35 (1.41)
Systolic blood pressure (mmHg), mean (SD) 134 (16)
Diastolic blood pressure (mmHg), mean (SD) 75 (10)
BMI (kg/m2), median [IQR] 29.8 [26.4–34.1]
Total cholesterol (mmol/L), median [IQR] 4.1 [3.5–4.7]
HDL cholesterol (mmol/L), median [IQR] 1.19 [1.00–1.40]
Medication, N (%)
Insulin 66,530 (59.1)
Other hypoglycaemic medication 33,061 (29.4)
Clinical outcomes, N (%)
Atrial fibrillation 1101 (1.058)
Chronic kidney disease 381 (0.349)
Chronic obstructive pulmonary disease 846 (0.801)
Table 1 Summary of study population (THIN database) by
practice and patient-level characteristics (Continued)
Ischaemic heart disease 967 (1.109)
Peripheral vascular disease 575 (0.545)
Stroke 458 (0.426)
BMI body mass index, HbA1c glycosylated haemoglobin, HDL high-density
lipoprotein, IQR interquartile range, SD standard deviation. Note: the percentage
corresponds to the number of applicable patients, and so the total may not be
identical for each outcome variable. aHere general practice size corresponds to
the number of patients within the general practice who have satisfied the entry
criteria (patients who had C10F Read (version 2) code for diabetes entered on the
Vision GP patient management system or other codes specifying type-2 diabetes)
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Only three trials reported ICCs from their analysis
[14, 38, 48]. Two trials reported ICCs for HbA1c %
[14, 48], with ICCs of 0.0253 and 0.02 (95 % CI
0.00–0.08), and one trial [38] reported an ICC for
blood pressure of 0.035. For the two trials that re-
ported the ICC, the reported value was lower than
the value used in the initial sample size calculation,
whilst for blood pressure the reported value was not-
ably higher. However, for the trial that estimated an
ICC for blood pressure [38], it was not clear what
method was used to estimate this value.
Discussion
Using THIN database, we have estimated ICCs for a var-
iety of outcomes associated with type-2 diabetes. We are
the first to report time-dependent correlations, the IPC
and WPC, which can be used in the design of cluster
cross-over and stepped wedge CRCTs. For binary out-
comes, we reported both the latent ICC (an ICC from a
logistic model) and the natural ICC on the proportion
scale (an ICC from a linear model).
These results are primarily applicable for planned
CRCTs aimed at the general practice level in the UK,
but in the absence of other estimates, may be useful
more widely. We found that the ICC for HbA1c used in
the design of trials tended to be larger than that esti-
mated here.
Intra-cluster correlation coefficients
ICCs were calculated for continuous and dichotomous
clinical measurements and outcomes, using both ad-
justed and unadjusted models. This includes ICCs for
continuous outcomes and ICCs for binary outcomes.
Upon adjusting for age, sex, location, and deprivation
quintiles, the ICCs were generally similar to the ICCs es-
timated from the unadjusted models (HbA1c 0.032 ver-
sus 0.032). Adjusting for confounding factors also had
minimal impact on the standard error of the ICCs
(HbA1c 0.003 versus 0.003).
There was a noticeable difference between natural
ICCs and latent ICCs for binary outcomes. Latent ICCs
estimated for clinical events were much larger than their
corresponding natural ICC. Similar results were found
by Wu et al. [52], who found that ICCs were smaller
when modelled using linear regression than logistic
regression.
For binary outcomes it is important to note that nat-
ural ICCs (an ICC from a linear model) are smaller for
Table 3 Summary of the variation of practice average values
from included patients from THIN database
Outcomes, median [IQR] Practice average
Age 68.4 [66.9–69.8]
Sex, (%) Male, 55 [53–58]
Clinical measures
HbA1c (%), median 7.05 [6.9–7.2]
Systolic blood pressure (mmHg), median 135 [132–137.5]
Diastolic blood pressure (mmHg), median 76 [74–78]
BMI (kg/m2), median 29.9 [29.2–30.6]
Total cholesterol (mmol/L), median 4.10 [3.90–4.18]
HDL cholesterol (mmol/L), median 1.18 [1.10–1.20]
Medication, (%)
Prescribed insulin 57.8 [48.0–68.6]
Prescribed other hypoglycaemic medication 29.2 [21.8–36.7]
Clinical outcomes (%)
Atrial fibrillation 0.909 [0.476–1.497]
Chronic kidney disease 0.000 [0.000–0.560]
Chronic obstructive pulmonary disease 0.708 [0.000–1.205]
Ischaemic heart disease 0.389 [0.000–0.862]
Peripheral vascular disease 0.371 [0.000–0.800]
Stroke 0.000 [0.000–0.667]
BMI body mass index, HbA1c glycosylated haemoglobin, HDL high-density lipo-
protein, IQR interquartile range. Note: the average outcome value/clinical
measure was calculated for each practice using mean or median as appropriate.
The average practice values were then summarised across practices by the
median and interquartile range
Table 2 Summary statistics for clinical measures of included patients from THIN database in binary form
Outcome Number of observations Number of patients exceeding measurement
Clinical measures, N (%)
HbA1c (%) (>7.5) 101,412 34,723 (34.2)
Systolic blood pressure (mmHg) (>140) 86,918 21,865 (25.2)
Systolic blood pressure (mmHg) (>130) 86,918 49,697 (57.2)
Diastolic blood pressure (mmHg) (>80) 86,918 20,403 (23.5)
BMI (kg/m2) (>30) 86,681 41,880 (48.3)
BMI (kg/m2) (>25) 86,681 72,062 (83.1)
Total cholesterol (mmol/L) (>4) 92,089 46,378 (50.4)
HDL cholesterol (mmol/L) (<1.2) 80,690 40,653 (50.3)
BMI body mass index HbA1c glycosylated haemoglobin, HDL high-density lipoprotein
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cases in which the prevalence’s are low [35, 53]. Here all
clinical outcomes chosen were rare events and conse-
quently had small prevalence’s. Since the dichotomised
values were chosen to reflect typical values in relation to
type-2 diabetes, the prevalence’s of these were naturally
larger – resulting in a larger ICC.
Due to the importance of the prevalence on the nat-
ural ICC, care should be taken to ensure that an appro-
priate ICC is used. If the prevalence in a planned trial
differs greatly from the prevalence used here, sample size
calculations using the natural ICC from these results
may be inaccurate
Since latent ICCs for dichotomous outcomes, are
estimated using logistic regression, they are on a log-
odds scale and so are defined on a different scale to
a natural ICC [35, 52]. A latent ICC estimated in this
manner will refer to an unobservable latent scale, ra-
ther than the correlation of observations within a
cluster, and so would not be a relevant ICC for use
in the design stage of a trial. Eldridge et al. [21] pro-
vide a table that allows some ICCs on this logistic
scale to be converted into a natural ICC for a selec-
tion of prevalence’s.
Previous trials
Many authors discuss the most appropriate methods
and models that should be used to model ICCs in situa-
tions in which the outcome is binary [35, 52, 54], and
there are numerous cases in which previous authors
have correctly estimated ICCs for binary outcomes using
linear models for future trialists to use [34, 55–57].
However, there are still some situations where a logistic
model is used [58–60]. The differences between the nat-
ural ICC and the latent ICC are also considered by
Merlo et al. [61] who note that since the natural ICC de-
pends on the prevalence of the outcome; any compari-
sons made regarding the magnitude of clustering should
be made using the latent ICC. We agree that that care
should be taken when using the natural ICC to describe
the extent of clustering in a trial with binary outcomes;
however, we cannot recommend that the latent ICC is
used directly in the design of future trials.
The number of previous cluster trials involving type-2
diabetes that have reported ICCs from their results is ra-
ther small, which will leave future trialists using ad hoc
values or conservative values. The ICCs found in this
paper were smaller than that often used in trials, but
more consistent with the ICCs that were reported from
the results of previous trials. The ICC for HbA1c %, the
most common outcome in a trial involving type-2 dia-
betes, was found to be 0.032 (SD 0.003). Trials in which
the primary outcome is binary should use an ICC from a
linear model when estimating a required sample size,
and not one obtained from a logistic model, even if the
data will be analysed using a logistic model.
Inter-period correlation coefficients
It is emerging that cluster designs require not only esti-
mates of within-cluster correlation measures, but some
value of how this correlation decays over time [29, 62].
We have attempted in part to address this issue and are
the first to provide estimates of the inter-period correl-
ation and the within-period correlation alongside ICCs.
However, we have only provided these estimates for con-
tinuous outcomes and we have only provided estimates
Fig. 1 Box plot highlighting the median, interquartile range, and range of the intra-cluster correlation coefficients (ICCs) that were estimated for
continuous and binary clinical outcomes from both linear and logistic models (n = number of outcomes that had estimate of the ICC)
Table 4 Intra-cluster correlation coefficients (ICCs) for
continuous outcomes for included patients from THIN database





HbA1c (%) 0.032 (0.003) 0.032 (0.003)
Systolic blood
pressure (mmHg)
0.031 (0.003) 0.029 (0.002)
Diastolic blood
pressure (mmHg)
0.039 (0.003) 0.039 (0.003)
BMI (kg/m2) 0.020 (0.002) 0.022 (0.002)
Total cholesterol
(mmol/L)
0.020 (0.002) 0.018 (0.002)
HDL cholesterol
(mmol/L)
0.021 (0.002) 0.020 (0.002)
BMI body mass index, HbA1c glycosylated haemoglobin, HDL high-density
lipoprotein, SE standard error
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Table 6 Estimates of the within-period and inter-period correlation for included patients from THIN database from two consecutive
periods
Unadjusted model Adjusted model
Outcome WPC IPC CA WPC IPC CA
(SE) (SE) (SE) (SE)
HbA1ca (%) 0.035 0.019 0.546 0.035 0.019 0.539
(0.003) (0.003) (0.003) (0.003)
Systolic blood pressureb (mmHg) 0.032 0.021 0.649 0.030 0.019 0.632
(0.003) (0.003) (0.002) (0.003)
Diastolic blood pressureb (mmHg) 0.040 0.028 0.692 0.040 0.026 0.662
(0.003) (0.004) (0.003) (0.004)
BMIb (kg/m2) 0.021 0.013 0.612 0.022 0.016 0.747
(0.002) (0.002) (0.002) (0.002)
Total cholesterolb (mmol/L) 0.021 0.010 0.486 0.021 0.006 0.281
(0.002) (0.002) (0.002) (0.002)
HDL cholesterolb (mmol/L) 0.021 0.018 0.876 0.020 0.017 0.889
(0.002) (0.002) (0.002) (0.002)
BMI body mass index, CA cluster autocorrelation, HbA1c glycosylated haemoglobin, HDL high-density lipoprotein, IPC inter-period correlation, SE standard error,
WPC within-period correlation. aTwo consecutive 12-month periods were used. bTwo consecutive 15-month periods were used
Table 5 Intra-cluster correlation coefficients (ICCs) for binary outcomes for included patients from THIN database












HbA1c (%) (>7.5) 0.342 0.035 (0.003) 0.037 (0.003) 0.026 (0.002) 0.027 (0.002)
Systolic blood pressure
(mmHg) (>140)
0.252 0.069 (0.005) 0.066 (0.005) 0.039 (0.003) 0.036 (0.003)
Systolic blood pressure
(mmHg) (>130)
0.572 0.047 (0.004) 0.044 (0.003) 0.038 (0.003) 0.035 (0.003)
Diastolic blood pressure
(mmHg) (>80)
0.235 0.086 (0.006) 0.088 (0.007) 0.046 (0.004) 0.045 (0.003)
BMI (kg/m2) (>30) 0.483 0.019 (0.002) 0.022 (0.002 0.015 (0.001) 0.016 (0.002)
BMI (kg/m2) (>25) 0.831 0.022 (0.002) 0.022 (0.002) 0.011 (0.001) 0.010 (0.001)
Total cholesterol
(mmol/L) (>4)
0.504 0.025 (0.002) 0.024 (0.002) 0.020 (0.002) 0.019 (0.002)
HDL cholesterol
(mmol/L) (<1.2)
0.503 0.035 (0.002) 0.036 (0.003) 0.029 (0.002) 0.027 (0.002)
Medication
Taking of insulin 0.591 0.113 (0.007) 0.109 (0.007) 0.081 (0.006) 0.077 (0.005)
Clinical outcomes
Atrial fibrillation 0.01058 0.020 (0.009) 0.016 (0.009) 0.001 (0.000) 0.001 (0.000)
Chronic kidney disease 0.00349 0.140 (0.026) 0.136 (0.026) 0.003 (0.000) 0.003 (0.000)
Chronic obstructive pulmonary disease 0.00801 0.070 (0.015) 0.064 (0.015) 0.002 (0.000) 0.002 (0.000)
Ischaemic heart disease 0.01109 0.027 (0.011) 0.027 (0.011) 0.001 (0.000) 0.001 (0.000)
Peripheral vascular disease 0.00545 0.130 (0.020) 0.124 (0.020) 0.005 (0.001) 0.005 (0.001)
Stroke 0.00426 0.274 (0.031) 0.261 (0.031) 0.010 (0.001) 0.010 (0.001)
BMI body mass index, HbA1c glycosylated haemoglobin, HDL high-density lipoprotein, SE standard error
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assuming a cross-sectional study design. Clearly, many
studies use a cohort design and many studies contain a
primary outcome that is dichotomous in nature. How-
ever, estimation of correlation coefficients for binary out-
comes are more complex due to the change of scale; and
adding a cohort structure would increase complexity, as
it would also be necessary to allow for within-person
correlation.
The IPC and WPC may also be reported as the CA. It
has been established that the sample size is directly im-
pacted by the CA [37]. No guidelines exist for reason-
able values of the CA, but values of 0.8 and 1.0 have
previously been used [28, 63]. Here we have shown that
for our study design, the CA may be smaller than these
estimates.
Ignoring the IPC and CA in sample size calculations
may lead to incorrect estimates of the required number
of clusters in a CRT [29] or to underpowered studies
[28]. Studies in which the IPC differs to the WPC should
ensure that the estimates of ρ for use in Eq. 1 stem from
the WCC estimated via Eq. 3, and not from an ICC esti-
mated by Eq. 2.
Future research
It has been established that the ICC, IPC, and CA are
necessary for sample size calculations for CRCTs. How-
ever, there is opportunity for future research into the
IPC and the impact of time between observations in the
model for CRCTs. It is perhaps naïve to assume a fixed
correlation between observations in a cluster trial re-
gardless of the time between these. Instead, this correl-
ation should depend on time, and this length of time
may be important. It is not known what impact chan-
ging the length of time period or the length of the study
period would have on the IPC. Additionally, the IPC
used to direct a sample size calculation should be calcu-
lated from a dataset using a similar time period and
study length. The motivating idea behind additional
correlation types is repeated cross-sectional designs
such as the cluster cross-over design and the stepped
wedge design. However, these results may indicate
that sample size in parallel CRCTs should also ac-
knowledge that correlation may be time-dependent.
Future research is likely to show that recognising the
decay in correlation over time in the model would
increase power in parallel designs.
Limitations
There are limitations that may arise from using routine
data from general practices. It is not always possible to
distinguish between follow-up care for a first clinical
event (e.g. myocardial infarction) from a second event as
they may have been coded in an identical manner. This
means that patients who had suffered an event prior to
the study inclusion period would have to be excluded
from the analysis. There is also the possibility of mis-
classification as type-2 diabetes rather than type-1 dia-
betes due to coding errors, which could lead to younger
patients being included in the study unintentionally.
Since THIN dataset consists of data from general prac-
tices only, the results can only be adjusted for variables
that are recorded by the practice. The quality of service
may vary between practices and so there may be situa-
tions in which clinical measures are monitored in
different intervals which, along with quality of reporting
and recording of measurements, could lead to an
inconsistency.
Table 7 Summary of systematic search of intra-cluster correlation coefficients (ICCs) used in previous trials
Trial author Outcome used ICC used Standard deviation used ICC reported
Bellary et al. [47] HbA1c 0.05 2.1
Dallosso et al. [50] HbA1c 0.05 1.5
Khunti et al. [14] HbA1c 0.05 2.0 0.02 (0.00–0.08)
Mathers et al. [49] HbA1c 0.047 1.5
Smith et al. [39] HbA1c 0.001 1.6
Smith et al. [51] HbA1c 0.047 1.5
Sturt et al. [48] HbA1c 0.047 0.0253
Bebb et al. [38] BP 0.02 Binary outcome 0.035
Bellary et al. [47] SBP 0.035 21.25
Smith et al. [39] SBP 0.001 Binary outcome
Bellary et al. [47] Cholesterol 0.05 1.1
Smith et al. [39] Cholesterol 0.06 Binary outcome
Here glycosylated haemoglobin (HbA1c) represents a difference in average HbA1c levels between patients in the control and intervention groups. SBP represents
systolic blood pressure, BP represents blood pressure – where a reading of both systolic and diastolic blood pressure was taken, and cholesterol represents total
cholesterol level
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Although the reporting of clinical measures during the
15-month cross-section that was chosen as the inclusion
period was high, the length of the cross-section may not
accurately represent the length of trials in practice.
Conclusions
An estimate of the ICC is vital when calculating the
sample size requirement in a pretrial calculation [21].
We estimated ICCs for a range of clinical outcomes re-
lated to type-2 diabetes that would be useful for plan-
ning a trial in UK primary care. The primary outcome
used in type-2 diabetes trials is often HbA1c, for which
we estimated an ICC of 0.032. We have also illustrated
how the methodology described here could be extended
for other outcomes or disease settings.
For binary outcomes, the results show careful consider-
ation is needed when estimating the ICC. This is because,
in a trial with a dichotomous outcome, the ICC used at the
design stage should refer to the variation in the observed
data rather than the underlying logistic scale. Despite the
analysis of binary outcomes being usually conducted via a
logistic regression model, the latent ICC obtained from
such model should not be used for sample size calculations.
Rather, the ICC used in the design stage of a trial should be
estimated from a linear mixed model on the natural scale.
In cluster trials with repeated cross-sections, observa-
tions are taken over multiple time periods. It is likely
that observations within a cluster within the same time
period are more highly correlated than observations
from different time periods. The inter-period correlation
and within-period correlation provides an estimate of
how this correlation deteriorates over time. We are the
first to report estimates of the IPC and WPC and we
have illustrated how these differ from the ICC. It may be
important to acknowledge the degeneration of correl-
ation over time in repeated cross-sectional studies.
Additional file
Additional file 1: Flow diagram of included trials for systematic search
of trials undertaken in primary care in type-2 diabetes. (PNG 17 kb)
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